

091-255888

For Internal Use Only		Submit 1 Original		OMB Approval No.:
Sec File No. 91 -		and 9 Copies		Expires:

Estimated average burden hours per response: 2.00

2018 SEP -5 AM 7:38  
SEC / TM

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

**READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM**

**Part I Initial Listing Report**

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

**New York Stock Exchange, LLC (trading pursuant to unlisted trading privileges)**

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

**Open-end Management Investment Company**

3. Class of New Derivative Securities Product:

**Investment Company Units**

4. Name of Underlying Instrument:

**Solactive Emerging Markets Healthcare Index**

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

**Narrow-Based**

6. Ticker Symbol(s) of New Derivative Securities Product:

**KMED**

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

**KOREA, SHENZHEN, HONG KONG, SHANGHAI, JSE, THAILAND, NASDAQ, BSE INDIA, SAO PAULO, BUDAPEST, MALAYSIA, INDONESIA**

8. Settlement Methodology of New Derivative Securities Product:

**Regular way trades settle on T+2/Book entry only held in DTC.**



9. Position Limits of New Derivative Securities Product (if applicable):

**Not applicable.**

18010428

**Part II Execution**

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

**Clare F. Saperstein**

Title:

**Associate General Counsel**

Telephone Number:

**(212) 656-2355**

Manual Signature of Official Responsible for Form:

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)

**August 31, 2018**

SEC 2449 (1/99)

Public Availability: **SEP 04 2018**



Clare F. Saperstein  
Associate General Counsel

New York Stock Exchange  
11 Wall Street  
New York, NY 10005  
T + 1 212 656 2355  
F + 1 212 656 8101  
Clare.Saperstein@theice.com

RECEIVED

SEP 05 AM 7:37

SEC / TM

Via Overnight Mail

August 31, 2018

SEC Mail Processing

SEP 04 2018

Washington, DC

Ms. Claudette Ransom  
US Securities and Exchange Commission  
Division of Trading and Markets  
Station Place – Building I  
100 F Street, N.E. – Room 7010  
Washington, DC 20549

**Re: 19b-4(e) – Transmittal (New York Stock Exchange, LLC)**

Dear Ms. Ransom:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

**Impact Shares YWCA Women's Empowerment ETF (WOMN)**  
**Global X Adaptive U.S. Factor ETF (AUSF)**  
**Innovator S&P 500 Buffer ETF – July (BJUL)**  
**KraneShares Emerging Markets Healthcare Index ETF (KMED)**

If you have any questions, please do not hesitate to call me at (212) 656-2355.

Sincerely,

Enclosures